Extraosseous effects of vitamin D: a role in the prevention and treatment of COVID-19?

Antonio Mirijello1 · Pamela Piscitelli1 · Cristina d’Angelo2 · Alberto Tosoni3 · Salvatore De Cosmo1

Received: 11 February 2022 / Accepted: 11 March 2022 / Published online: 28 March 2022 © The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022

Keywords Cholecalciferol · Calcifediol · Sars-Cov-2 infection · Viral sepsis

The article by Israel et al. recently published on Internal and Emergency Medicine [1] tries to shed light on the question whether vitamin D status could influence the risk of infecting from SARS-CoV-2 and of developing a severe disease. Authors retrospectively evaluated data from a large population cohort from Israel using a healthcare service registry [1].

First, Authors compared characteristics of 130,582 subjects testing positive for SARS-CoV-2 during the first pandemic wave (Mar–Oct 2020) with the whole CHS population (4,502,455 subjects) testing negative for the new coronavirus. Of these, 1,350,000 subjects had tested at least once during previous 10 years their serum vitamin D levels. Authors found that vitamin D levels were significantly lower among infected patients, particularly female. Moreover, besides lower vitamin D levels, those testing positive for SARS-CoV-2 showed a slightly higher BMI.

To eliminate confounders, a total of 41,757 patients testing positive for the new coronavirus were matched per age, gender, geographic region, and socioeconomic status with control subjects (ratio 1:10). Differences observed between cases and controls in terms of vitamin D levels, ethnic group, and BMI distributions in the matched cohort were similar to the unmatched population. Low vitamin D levels, particularly its severe deficiency (< 30 nmol/L), significantly predicted the risk of SARS-CoV-2 infection (OR = 1.442, 95% CI 1.392–1.494), the lower the levels, the higher the risk. Moreover, the risk of infection was significantly increased by comorbidities (e.g. chronic renal failure, congestive heart failure, diabetes, obesity). However, in multivariable models, the association between poor vitamin D status and infection persisted even after adjusting for BMI, ethnicity and comorbidities.

Finally, 2533 patients hospitalized for COVID-19 were compared (1:1 ratio) with patients who developed the infection but not required hospitalization, to test the association between vitamin D levels and disease severity. Again, low vitamin D levels significantly associated with the risk of hospitalization for severe disease (deficiency OR = 1.777, 95% CI 1.477–2.138; insufficiency OR = 1.256, 95% CI 1.057–1.492). Even this association persisted even after adjusting for BMI, ethnicity and comorbidities.

The paper by Israel and Colleagues represents one of the broadest observational study supporting the association between vitamin D deficiency and both the risks of infection and of severe COVID-19 [1].

This study comes with strengths and limitations. The significantly large population used as reference and the single geographic area represents the main strengths. On the contrary, the use of historical vitamin D levels (up to 10 years backwards) instead of those measured during acute infection represents a significant study limitation. Moreover, although vitamin D was independently associated with the outcomes, it is noteworthy to underline that even comorbidities associated with endpoints are typically characterized by vitamin D deficiency. In addition, information on eventual vitamin D supplementation is lacking. With this regard, authors considered the last available vitamin D value, arguing that subjects taking vitamin supplements would have been retested for plasmatic levels after treatment. Assuming this hypothesis
as possibly true, it should also be said that vitamin D levels measured during “healthy state” are more reliable than those measured during infection, because serum vitamin D concentrations could be lowered by acute inflammatory states [2]. However, the main limitation of this study resides in its retrospective, observational, non-interventional design [1]. Nevertheless, observed results are in line with a recent meta-analysis of observational studies confirming the increased susceptibility to COVID-19 and severe COVID-19 among patients with vitamin D deficiency/insufficiency [3].

In the last decades, “nonclassical” effects of vitamin D, particularly its immunomodulating effects have been extensively studied [4]. The possible role of vitamin D in regulating both innate and adaptive immunity led to the design of several clinical trials exploring its effects in different fields, including metabolic [5], autoimmune [6, 7] and infectious [8] disorders. For what concerns its role against infections, vitamin D stimulates the production of antimicrobial peptides [9] with most of the knowledge coming from sepsis [10, 11]. It should be underlined that the COVID-19 syndrome has several similarities with sepsis, being defined by some authors a “viral sepsis” [9]. Specifically, the role of vitamin D against viruses helps in maintaining cellular barriers (e.g. tight and gap junctions), producing cathelicidins and defensins (natural immunity), balancing TH1/TH2 response (adaptive immunity) [12], and reducing pro-inflammatory cytokines and cytokine storm [13].

Vitamin D supplementation in COVID-19 patients has a rationale [1, 3, 14]; however, its optimal dosing, levels, form, and route of administration are still matter of debate [15]. It is conceivable that target levels could vary depending on indication (e.g. bone metabolism, prevention of infections, inhibition of autoimmune response, etc.). As per COVID-19, most of studies suggest a target of 30 ng/mL (75 nmol/L) [16]. However, despite the consensus on the use of 25-hydroxyvitamin D concentrations as a marker of vitamin D storages [15], there are still no indications to prefer cholecalciferol or its activated metabolites for treating vitamin D deficiency/insufficiency. Probably, the administration of calcifediol is able to raise vitamin D concentrations more rapidly (i.e. hours) than cholecalciferol (i.e. days) [17]. However, if this could translate in a clinical benefit has still to be demonstrated.

At present, interventional studies assessing the potential role of vitamin D supplementation for preventing infection and death from COVID-19 are few [18–20], and most of them still ongoing [21, 22]. A recent review and meta-analysis of randomized controlled trials on COVID-19 and vitamin D (Co-VIVID study) found 6 high-quality studies for a total of 551 COVID-19 patients included [23]. Despite the limited number of patients, the pooled effect of vitamin D administration resulted in a 40% relative risk reduction of overall COVID-19-related outcomes [RR = 0.60, (95% CI 0.40–0.92)] and a 56% relative risk reduction for RT-PCR positivity [RR = 0.46, (95% CI 0.24–0.89)] [23]. However, despite its possible global beneficial effect, analysed data did not find a significant association between vitamin D supplementation and an improvement of hard outcomes (e.g. admission to ICU and death). Authors conclude highlighting the need for future robust interventional trials [23].

As already evidenced from studies conducted in the field of critically ill septic patients, it is still unknown if reduced levels of vitamin D represent the causative mechanism for susceptibility to infections (e.g. sepsis, COVID-19), the effect of greater peripheral catabolism due to inflammation [2, 24], or the marker of a comorbid state (e.g. diabetes, obesity, frailty) [23].

As a matter of fact, those patients presenting with a poor vitamin D status are at higher risk for worse outcomes [1, 11, 14] and the immunomodulatory effects of vitamin D have a pathophysiological rationale [25]. While waiting for robust evidences supporting the administration of vitamin D in the acute phase of disease, available data favour vitamin D supplementation at a population basis, at least in those subjects showing deficiency/insufficiency, to enhance innate immune function against SARS-CoV-2 [12], under the shield of vaccines, independently from SARS-CoV-2 variants.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Human and animal rights statement This commentary is the original work of the named authors, who reviewed previously published information. No new human or animal studies were performed by the authors.

Informed consent For this type of study, no informed consent is required.

References

1. Israel A, Cicurel A, Feldhamer I, Stern F, Dror Y, Giveon SM et al (2022) Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection and COVID-19 severity: a retrospective case-control study. Intern Emerg Med. https://doi.org/10.1007/s11739-021-02902-w
2. Smolders J, van den Ouweel J, Geven C, Pickkers P, Kos M (2021) Letter to the Editor: vitamin D deficiency in COVID-19: mixing up cause and consequence. Metabolism 115:154434
3. Dissanayake HA, de Silva NL, Sumanatilleke M, de Silva SDN, Gamage KKK, Dematapitiya C et al (2021) Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgab892
4. Adams JS, Hewison M (2008) Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 4:80–90
5. Cai B, Luo X, Zhang P, Luan Y, Cai X, He X (2021) Effect of vitamin D supplementation on markers of cardiometabolic risk in children and adolescents: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 31(10):2800–2814
6. Martinez-Lapiscina EH, Mahatanan R, Lee CH, Charoenpong P, Hong JP (2020) Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis. J Neurol Sci 411:116668
7. Schneider L, Hax V, Monticielo O, Macedo TF, Barreto RKM, Marcondes NA et al (2021) Dualities of the vitamin D in systemic sclerosis: a systematic literature review. Adv Rheumatol 61(1):34
8. Amrein K, Schnell C, Holl A, Riedl R, Christopher KB, Pachler C et al (2014) Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VIT-dAL-ICU randomized clinical trial. JAMA 312(15):1520–1530
9. Rossetti M, Martucci G, Starchl C, Amrein K (2021) Micronutrients in sepsis and COVID-19: a narrative review on what we have learned and what we want to know in future trials. Medicina (Kaunas) 57(5):45
10. Mirijello A, Tosoni A, Zaccone V, Impagnatiello M, Passaro G, Vallone CV et al (2019) MEDS score and vitamin D status are independent predictors of mortality in a cohort of Internal Medicine patients with microbiological identified sepsis. Eur Rev Med Pharmacol Sci 23(9):4033–4043
11. Li Y, Ding S (2020) Serum 25-hydroxyvitamin D and the risk of mortality in adult patients with sepsis: a meta-analysis. BMC Infect Dis 20(1):189
12. Mirijello A, D’Errico MM, La Marca A, Piscitielli P, De Cosmo S (2020) Comment on Matricardi PM et al. Pediatr Allergy Immunol 31(8):997
13. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL et al (2020) Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 12(4):988
14. Chiodini I, Gatti D, Soranna D, Merlotti D, Mingiano C, Fassio A et al (2021) Vitamin D status and SARS-CoV-2 infection and COVID-19 clinical outcomes. Front Public Health 9:736665
15. Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lazaretto-Castro M, Marcocci C, Napoli N, Rizzoli R, Giustina A (2021) Vitamin D: dosing, levels, form, and route of administration: does one approach fit all? Rev Endocr Metab Disord 22(4):1201–1218. https://doi.org/10.1007/s11154-021-09693-7
16. Bahat G, Erbas Sacar D, Petrovic M (2021) Vitamin D in patients with COVID-19: is there a room for it? Acta Clin Belg 20:1–7. https://doi.org/10.1080/17843286.2021.1918332
17. Grant WB (2021) Vitamin D’s role in reducing risk of SARS-CoV-2 and COVID-19 incidence, severity, and death. Nutrients 14(1):183. https://doi.org/10.3390/nu14010183
18. Gönen MS, Alayışoğlu M, Durcan E, Özdemir Y, Şahin S, Konukoğlu D, Nohut OK, Ürkmez S, Kıcıkçe B, Balkan İ, Karav H, Börekcı Ş, Özkaya H, Kutlubay Z, Dikmen Y, Keskinemirci Y, Karas SN, Anweiler C, Gezen-Ak D, Dursun E (2021) Rapid and effective vitamin D supplementation may present better clinical outcomes in COVID-19 (SARS-CoV-2) patients by altering INOS1, IL1B, IFNγ, cathelicidin-L37, and ICAM1. Nutrients 13(11):4047. https://doi.org/10.3390/nu13114047
19. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, Quesada Gomez JM (2020) Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol 203:105751. https://doi.org/10.1016/j.jsbmb.2020.105751
20. Alcalá-Díaz JF, Limia-Perez L, Gomez-Huelgas R, Martín-Escalante MD, Cortes-Rodriguez B, Zambrana-Garcia JL, Entrenas-Castillo M, Perez-Caballero AI, López-Carmona MD, Garcia-Alegria J, Lozano Rodriguez-Mancheño A, Arenas-de Larriva MDS, Pérez-Belmonte LM, Jungreis I, Bouillon R, Quesada-Gomez JM, Lopez-Miranda J (2021) Calcifediol treatment and hospital mortality due to COVID-19: a cohort study. Nutrients 13(6):1760. https://doi.org/10.3390/nu13061760
21. Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections (CORONAVIT). https://clinicaltrials.gov/ct2/show/NCT04579640 (Accessed 26 Feb 2022)
22. COVID-19 and Vitamin D supplementation: a multicenter randomized controlled trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients (CoVitTrial). https://clinicaltrials.gov/ct2/show/NCT04344041 (Accessed 26 Feb 2022)
23. Varikasuvu SR, Thangappazham B, Vy kunta A, Duggina P, Manne M, Raj H et al (2022) COVID-19 and vitamin D (CO-VIVID study): a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther. https://doi.org/10.1080/14787210.2022.2035217
24. Koekkoek WA, van Zanten AR (2016) Vitamin D deficiency in critically ill. Ann Med 48(5):301–304
25. Dhawan M, Priyanka COP (2022) Immunomodulatory and therapeutic implications of vitamin D in the management of COVID-19. Hum Vaccin Immunother. https://doi.org/10.1080/21645515.2022.2025734